Article Text

Download PDFPDF

Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy
  1. Juan Fu1,
  2. Young Kim2,
  3. David Kanne3,
  4. Meredith Leong4,
  5. Qi Zeng2,
  6. Rupashree Sen5,
  7. Todd D Amstrong6,
  8. Charles G Drake7,
  9. Thomas Dubensky4,
  10. Drew Pardoll2 and
  11. Shekhar Gadkare2
  1. Aff1 grid.21107.350000000121719311Johns Hopkis Unversity Baltimore MD USA
  2. Aff2 grid.21107.350000000121719311Johns Hopkins University Baltimore MD USA
  3. Aff3 grid.417411.6Aduro BioTech Berkeley CA USA
  4. Aff4 grid.417411.6Aduro BioTech Berkely CA USA
  5. Aff5 grid.21107.350000000121719311Johns Hopkins Unversity Baltimore MD USA
  6. Aff6 grid.21107.350000000121719311Johns Hopins University Baltimore MD USA
  7. Aff7 grid.21107.350000000121719311Department of OncologySidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Baltimore MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

One important barrier to cancer immunotherapy. We used cyclic dinucleotides (CDNs) and Listeria vaccine and LPS treated HA-specific CD8 tolerance B10. D2 mice. Our results demonstrated T cells IFN-gamma increased in CDNs and Listeria vaccine plus CDNs treatment groups. But CDNs didn't significantly increase Treg cells. The data showed CDNs can reverse established T cell tolerance that improved cancer immunotherapy in the future. We will further explore T cells tolerance in cancer bearing T cell tolerance mice model in vivo.